五月天婷亚洲视频网,国产人妻久久久精品麻豆,天美传媒MV免费观看软件的特点

您好，歡迎來(lái)到拜力生物網(wǎng)站！請(qǐng)登錄注冊(cè)

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時(shí)間：08:30-17:30

主營(yíng)產(chǎn)品： ELISA試劑盒、抗體、補(bǔ)體血清、兔補(bǔ)體、干擾素、小鼠測(cè)溫儀、進(jìn)口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁(yè) 產(chǎn)品中心代理品牌新聞資訊資源中心關(guān)于我們

所在位置：首頁(yè) > 產(chǎn)品中心 > Antibodies > Antibodies產(chǎn)品

訂購(gòu)信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-Phospho-MAPT-S262 Antibody

品牌：Antibodies

貨號(hào)：

規(guī)格：50μl

貨期：

應(yīng)用：

咨詢客服

立即購(gòu)買加入購(gòu)物車

Anti-Phospho-MAPT-S262 Antibody

商品詳情參考文獻(xiàn) 相關(guān)資料

Overview

Name:	Anti-Phospho-MAPT-S262 Antibody See all MAPT primary antibodies
Description:	Rabbit polyclonal antibody to Phospho-MAPT-S262.
Applications:	WB, IHC, IF
Dilutions:	WB: 1:500 - 1:2000, IHC: 1:50 - 1:100, IF: 1:100 - 1:200.
Reactivity:	Human, Mouse, Rat
Immunogen:	A phospho specific peptide corresponding to residues surrounding S262 of human MAPT.
Protein Length:	758
Host:	Rabbit
Clonality:	Polyclonal
Isotype:	IgG
Conjugate:	Unconjugated
Purification:	Affinity purification.
Product Form:	Liquid
Formulation:	Supplied in Phosphate Buffered Saline, pH 7.30, with 0.02% Sodium Azide and 50% Glycerol.
Storage:	Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Target

Function:	Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
Tissue Specificity:	Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
Involvement in Disease:	Frontotemporal dementia: A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. Pick disease of the brain: A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration. Progressive supranuclear palsy 1: Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. Parkinson-dementia syndrome: A syndrome characterized by parkinsonism, tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.
Post-Translational Modification:	Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tau/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717. Dephosphorylated at several serine and threonine residues by the serine/threonine phosphatase PPP5C.
Cellular Location:	Cytoplasm > Cytosol. Cell membrane. Cytoplasm > Cytoskeleton. Cell projection > Axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.